当前位置: X-MOL 学术Nat. Rev. Nephrol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors
Nature Reviews Nephrology ( IF 28.6 ) Pub Date :  , DOI: 10.1038/nrneph.2017.140
Berthold Hocher , Oleg Tsuprykov

Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors

Nature Reviews Nephrology, Published online: 9 October 2017; doi:10.1038/nrneph.2017.140

New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2 diabetes mellitus. The renoprotective efficacy of liraglutide is not, however, as great as that reported for the sodium-glucose cotransporter 2 inhibitor emplagiflozin in the EMPA-REG OUTCOME trial.



中文翻译:

糖尿病肾病:GLP1R激动剂和SGLT2抑制剂的肾脏保护作用

糖尿病肾病:GLP1R激动剂和SGLT2抑制剂的肾脏保护作用

Nature Reviews Nephrology,在线发布:2017年10月9日;doi:10.1038 / nrneph.2017.140

LEADER试验的新数据表明,胰高血糖素样肽1受体激动剂利拉鲁肽可预防2型糖尿病患者的糖尿病肾病。但是,利拉鲁肽的肾脏保护功效不如EMPA-REG OUTCOME试验中报道的钠-葡萄糖共转运蛋白2抑制剂依普拉替洛嗪的。

更新日期:2017-10-11
down
wechat
bug